Owings Mills, Md. – (June 4, 2009)
– Clinical Trials & Surveys Corp. (C-TASC), a clinical trials solutions company, announced today that it has relocated its corporate headquarters to Owings Mills in Baltimore County. Specializing in the support of best practices management of clinical trials, clinical cohort studies, case/control studies, clinical registries and laboratory studies, C-TASC now occupies 17,000 square-feet of office space at 10065 Red Run Boulevard – more than twice the size of its previous facility.
Formerly headquartered in Baltimore City, the move was necessary to accommodate the rapid expansion of the C-TASC staff, which has added more than 10 full-time employees within the last year. Currently a staff of 40, the company plans to continue to grow to at least 60 employees by February 2010.
This significant growth is a result of the increased demand for C-TASC’s clinical trials services and technologies. In 2008, C-TASC won numerous new contracts to coordinate multi-center clinical trials, including its current work with the National Institutes of Child Health and Human Services (NICHHD), New York University (NYU), Johns Hopkins University School of Medicine and the Food and Drug Administration (FDA).
Much of C-TASC’s recent success can be attributed to the development and utilization of its proprietary Web-based data management application suite, known as StudyCTMSTM, which enables investigators to easily develop and manage clinical studies and deliver the accumulated data and metadata in an easy-to-read and FDA-acceptable format.
“We have been very fortunate over the last year to be in the position to bring in new staff to support the many federal and private contracts that have been awarded to us, however as a result, we rapidly outgrew our previous office space,” said Dr. Bruce Thompson, president, C-TASC. “After evaluating many different sites, Owings Mills provided us with the best location to fit our current needs while leaving us room to continue to grow comfortably throughout 2009 and beyond.”
About C-TASC
Based near Baltimore, Clinical Trials & Surveys Corp. (C-TASC) is a clinical trials solutions company that has supported best practices management of clinical trials and studies for government, university and private organizations since 1989. C-TASC has a successful research history in cancer, cardiovascular disease, AIDS, pulmonary disease, Cystic Fibrosis, sleep disorders and pharmaco-epidemiology. C-TASC’s software group utilizes the firm’s StudyCTMSTM product suite to provide investigators with complete Web-based trial management designed to deliver FDA-acceptable data. The C-TASC professional services group provides expert consultation in all areas of clinical trial management including medical and statistical study design, project management, data conversion including FDA SDTM formatting, performance monitoring, data quality control and analysis as well as support for study publication and presentation. For more information about C-TASC’s projects, products and services, please visit
www.c-tasc.com
.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
POETYK PsA-2 Trial Shows Efficacy of Sotyktu as an Oral Therapy for Psoriatic Arthritis
March 11th 2025Sotyktu (deucravacitinib) demonstrated significant efficacy in improving psoriatic arthritis symptoms compared to placebo in the Phase III POETYK PsA-2 trial, with a well-tolerated safety profile.